

# WHO policy on collaborative TB/HIV activities

Guidelines for national  
programmes and  
other stakeholders



World Health  
Organization

This is an updated version of a document originally published in 2004 as *Interim policy on collaborative TB/HIV activities* (WHO/HTM/TB/2004.330; WHO/HTM/HIV/2004.1)

WHO Library Cataloguing-in-Publication Data

WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders.

Contents: Annexes for webposting and CD-ROM distribution with the policy guidelines

1.HIV infections. 2.Acquired immunodeficiency syndrome - prevention and control. 3.AIDS-related opportunistic infections - prevention and control. 4.Tuberculosis, Pulmonary - prevention and control. 5.National health programs. 6.Health policy. 7.Guidelines. I.World Health Organization.

ISBN 978 92 4 150300 6 (NLM classification: WC 503.5)

These guidelines were developed in compliance with the process for evidence gathering, assessment and formulation of recommendations, as outlined in the *WHO handbook for guideline development* (version March 2010).

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by Creative Lynx, Geneva, Switzerland

Printed in Italy

WHO/HTM/TB/2012.1

WHO/HIV/2012.1

# **WHO policy on collaborative TB/HIV activities**

Guidelines for national programmes  
and other stakeholders



**World Health  
Organization**

### Summary of declaration of interests

All members of the Policy Updating Group were asked to complete a World Health Organization (WHO) *Declaration of interests for WHO consultants* form. Five members of the group declared a conflict of interest. Constance Benson declared consulting, scientific and technical advisory work on antiretroviral therapy new drug development with Merck, GlaxoSmithKline and ViiV for less than US\$ 5000 each. Pedro Cahn declared ongoing research support and consulting work with Abbott for an amount of US\$ 3000. He declared receiving US\$ 2000 from Bristol-Myers Squibb and US\$ 2000 from Tibotec for serving on a speakers' bureau. He also declared scientific advisory work for Merck, Pfizer, GlaxoSmithKline and Avexa for an amount of US\$ 2000 each. Mark Harrington declared giving testimony to the Institute of Medicine of the United States National Academies in panels on multidrug-resistant TB in 2008 and 2009. Charles Holmes declared employment by Gilead up to January 2008 in the clinical research unit focusing on phase I studies of experimental antiretroviral drugs. He declared no financial or other interest in Gilead. Salim S. Abdool Karim declared receiving US\$ 2500 from Merck to attend the advisory panel meeting on microbicides in March 2011.

The declared conflicts of interest were discussed within the WHO Steering Group and with the Policy Updating Group before deliberations on the policy document, and it was concluded that these conflicts would not prohibit any of the members from participating in the process. Declarations of interest were collected from all non-WHO reviewers. Four peer reviewers declared potential conflicts of interest. Helen Ayles declared an ongoing research grant for her research unit with Delft Diagnostic Systems of € 100 000 to develop a computer-aided diagnostic for reading digital chest X-rays as well as having received a digital chest X-ray unit for an amount of US\$ 250 000. François Boillot declared being the owner, director of and employed by a consulting company providing services in international health including in TB/HIV issues. Susan Swindells declared consulting services (advisory board) with Pfizer in 2008 (US\$ 1800) and 2009 (US\$ 1750), with Merck in 2009 (US\$ 3500), with Tibotec in 2009 (US\$ 1500) and with Abbott Molecular in 2010 (US\$ 1000). She also declared previous research support to her institution from Bristol Myers Squibb that ended in 2010 (US\$ 14929), from Pfizer that ended in 2011 (US\$ 28125) and ongoing research support from GlaxoSmithKline for an amount of US\$ 104034 and US\$ 60676. Jay K. Varma declared non-monetary support (supplies and equipment) in 2010 valued at approximately US\$ 10 000 from Cellectis to the government research unit of China and collaborators in Inner Mongolia to examine the prevalence of TB in health-care workers in collaboration with the United States Centers for Disease Control and Prevention. The WHO Steering Group discussed these declarations and concluded that they would not exclude the reviewers from the process. All declarations of conflict of interests are retained on electronic file by the WHO Stop TB Department.

### Acknowledgements

The development of these guidelines was financially supported by the Joint United Nations Programme on HIV/AIDS Unified Budget and Workplan (UNAIDS UBW) and the US President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Centers for Disease Control and Prevention (CDC) and the United States Agency for International Development (USAID). Partial support for the systematic reviews on TB and HIV service integration was provided by the Global Fund to Fight AIDS, TB and Malaria.

**WHO policy on collaborative TB/HIV activities: Guidelines for national programmes and other stakeholders** is based on the interim policy on collaborative TB/HIV activities published in 2004 by the World Health Organization (WHO) and written by Haileyesus Getahun, Jeroen van Gorkom, Anthony Harries, Mark Harrington, Paul Nunn, Jos Perriens, Alasdair Reid and Marco Vitoria on behalf of the TB/HIV policy writing committee for the Global TB/HIV Working Group of the Stop TB Partnership. This updated policy was written by Delphine Sculier and Haileyesus Getahun (Stop TB Department, WHO) in collaboration with the WHO Steering Group.

### **WHO Steering Group**

Rachel Baggaley (HIV/AIDS Department), Haileyesus Getahun (Stop TB Department), Reuben Granich (HIV/AIDS Department), Christian Gunneberg (Stop TB Department), Craig McClure (HIV/AIDS Department), Eyerusalem Negussie (HIV/AIDS Department), Delphine Sculier (Stop TB Department), Marco Vitoria (HIV/AIDS Department).

### **WHO consultants for systematic and GRADE reviews**

Martina Penazzato (Italy), Amitabh Suthar (USA), Helena Legido-Quigley (UK).

### **Policy updating group**

Yibeltal Assefa (Federal HIV/AIDS Prevention and Control Office, Ethiopia), Abdool Karim S. Abdool Salim (Centre for the AIDS Programme of Research in South Africa, South Africa), Rifat Atun (Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund), Switzerland), Constance Benson (University of California, San Diego, USA), Amy Bloom (United States Agency for International Development (USAID), USA), Pedro Cahn (Fundación Huésped, Argentina), Rolando Cedillos (Proyecto Regional VIH SIDA para Centroamérica, El Salvador), Richard E. Chaisson (Johns Hopkins Bloomberg School of Public Health Center for TB Research, USA), Jeremiah Chakaya (Kenya Medical Research Institute (KEMRI), Kenya), Lucy Chesire (Advocacy to Control TB Internationally, Kenya), Mean Chhi Vun (National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Cambodia), Gavin Churchyard (Aurum Institute for Health Research, South Africa), William Coggin (Office of the US Global AIDS Coordinator (OGAC), USA), Riitta Dlodlo (International Union Against Tuberculosis and Lung Disease (The Union), Zimbabwe), Ade Fakoya, (The Global Fund, Switzerland), Peter Godfrey-Fausset (London School of Hygiene & Tropical Medicine, UK), Anthony Harries (The Union, UK), Mark Harrington (Treatment Action Group, USA), Diane Havlir (University of California, San Francisco, USA), Charles Holmes (OGAC, USA), Nina Kerimi (United Nations Office on Drugs and Crime, Kazakhstan), Robert Makombe (United States Centers for Disease Control and Prevention (CDC), Botswana), Bess Miller (Global AIDS Program, USA), Ya-Diul Mukadi (USAID, USA), Jintanta Ngamvithayapong-Yanai (Research Institute of Tuberculosis, Japan), Alasdair Reid (Joint United Nations Programme on HIV/AIDS, Switzerland), BB Rewari (National AIDS Control Organization, India), Ashurova Rukshona (National Center for Prevention and Control of AIDS, Tajikistan), Holger Schünemann (McMaster University Health Sciences Centre, Canada), Lakhbir Singh Chauhan (Central TB Division, Ministry of Health and Family Welfare, India), Joseph Sitienei (Division of Leprosy, TB and Lung Diseases, Kenya), Alena Skrahina (Republican Scientific and Practical Center of Pulmonology and Tuberculosis, Belarus), John Stover (Future Institutes, USA), Jeroen van Gorkom (KNCV Tuberculosis Foundation, Netherlands).

### **External peer reviewers**

Helen Ayles (ZAMBART Project, Zambia), François-Xavier Blanc (Agence nationale de recherche sur le sida et les hépatites virales, France), François Boillot (Alter-Santé Internationale et Développement, France), John T. Brooks (CDC, USA), Kevin Cain (KEMRI/CDC, Kenya), Wafaa El-Sadr (Columbia University, New York, USA), Eric Goemare (Médecins Sans Frontières (MSF), South Africa), Yared Kebede Haile (KNCV Tuberculosis Foundation, Netherlands), Steve D. Lawn (University of Cape Town, South Africa), Gary Maartens (University of Cape Town, South Africa), Barbara J. Marston (CDC, USA), Elizabeth Marum (CDC, Zambia), Max Meis (KNCV Tuberculosis Foundation, Netherlands), Sue Perez (free lance consultant, USA), Eric S. Pevzner (CDC, USA), Yogan Pillay (Strategic Health Programme, Department of Health, South Africa), Peter Saranchuk (MSF, South Africa), Kenly Sikwese (Global Network of People Living with HIV/AIDS, Zambia), Susan Swindells (University of Nebraska Medical Center, USA), Javid Syed (Treatment Action Group, USA), Nonna Turusbekova (KNCV Tuberculosis Foundation, Netherlands), Marieke van der Werf (KNCV Tuberculosis Foundation, Netherlands), Eric van Praag (Family Health International, United Republic of Tanzania), Jay K. Varma (CDC, China), Lynne Wilkinson (MSF, South Africa), Rony Zachariah (MSF, Belgium).

### **WHO headquarters and regional offices**

Leopold Blanc (Stop TB Department), Puneet Dewan (Regional Office for South-East Asia), Gottfried Hirsenschall (HIV/AIDS Department), Khurshid Hyder (Regional Office for South-East Asia), Rafael Lopez Olarte (Regional Office for the Americas), Frank Lule (Regional Office for Africa), Mario Raviglione (Stop TB Department), Ying-Ru Lo (HIV/AIDS Department), Caoimhe Smyth (HIV/AIDS Department).

### **Editor**

Karin Ciceri

### **Coordination**

Delphine Sculier and Haileyesus Getahun (Stop TB Department, WHO).

# Contents

<b>Abbreviations</b>	7
<b>Executive summary</b>	8
<b>1. Background and process</b>	10
1.1 Introduction	10
1.2 Scope of the policy	10
1.3 Target audience	10
1.4 Process of updating the policy	11
1.5 Quality of evidence and strength of recommendation	12
1.6 Adaptation of the policy	13
<b>2. Goal and objectives of collaborative TB/HIV activities</b>	14
<b>3. Recommended collaborative TB/HIV activities</b>	14
<b>A Establish and strengthen the mechanisms for delivering integrated TB and HIV services</b>	15
<b>A.1. Set up and strengthen a coordinating body for collaborative TB/HIV activities functional at all levels</b>	15
<b>A.2. Determine HIV prevalence among TB patients and TB prevalence among people living with HIV</b>	16
<b>A.3. Carry out joint planning to integrate the delivery of TB and HIV services</b>	17
A.3.1. Models of integrated TB and HIV service delivery	18
A.3.2. Resource mobilization and capacity building	19
A.3.3. Involving nongovernmental and other civil society organizations and communities	19
A.3.4. Engaging the private-for-profit sector	20
A.3.5. Addressing the needs of key populations: women, children and people who use drugs	20
A.3.6. Advocacy and communication	20
A.3.7. Operational research to scale up collaborative TB/HIV activities	20
<b>A.4. Monitor and evaluate collaborative TB/HIV activities</b>	21
<b>B Reduce the burden of TB in people living with HIV and initiate early antiretroviral therapy (the Three I's for HIV/TB)</b>	22
<b>B.1. Intensify TB case-finding and ensure high-quality antituberculosis treatment</b>	22
<b>B.2. Initiate TB prevention with Isoniazid preventive therapy and early antiretroviral therapy</b>	23
<b>B.3. Ensure control of TB Infection in health-care facilities and congregate settings</b>	25
<b>C Reduce the burden of HIV in patients with presumptive and diagnosed TB</b>	26
<b>C.1. Provide HIV testing and counselling to patients with presumptive and diagnosed TB</b>	26
<b>C.2. Introduce HIV prevention interventions for patients with presumptive and diagnosed TB</b>	27
<b>C.3. Provide co-trimoxazole preventive therapy for TB patients living with HIV</b>	28
<b>C.4. Ensure HIV prevention interventions, treatment and care for TB patients living with HIV</b>	28
<b>C.5. Provide antiretroviral therapy for TB patients living with HIV</b>	29
<b>4. National targets for scaling up collaborative TB/HIV activities</b>	30
<b>5. References</b>	31

## Abbreviations

---

<b>AIDS</b>	acquired immunodeficiency syndrome
<b>ART</b>	antiretroviral therapy
<b>ARV</b>	antiretroviral
<b>BCG</b>	Bacille Calmette–Guérin (vaccine)
<b>CBO</b>	community-based organization
<b>CPT</b>	cotrimoxazole preventive therapy
<b>DOT</b>	directly-observed treatment
<b>DOTS</b>	the basic package that underpins the Stop TB Strategy
<b>GRADE</b>	grading of recommendations assessment, development and evaluation
<b>GRC</b>	guidelines review committee
<b>HCW</b>	health-care worker
<b>HIV</b>	human immunodeficiency virus
<b>IPT</b>	isoniazid preventive therapy
<b>MCH</b>	maternal and child health
<b>MDG</b>	Millennium Development Goal
<b>NGO</b>	nongovernmental organization
<b>PMTCT</b>	prevention of mother-to-child transmission
<b>PICO</b>	population, intervention, comparison, outcome
<b>TB</b>	tuberculosis
<b>TB/HIV</b>	the intersecting epidemics of TB and HIV
<b>TST</b>	tuberculin skin test
<b>UNAIDS</b>	Joint United Nations Programme on HIV/AIDS
<b>WHO</b>	World Health Organization

## Executive summary

In 2004, the World Health Organization (WHO) published an interim policy on collaborative TB/HIV activities in response to demand from countries for immediate guidance on actions to decrease the dual burden of tuberculosis (TB) and human immunodeficiency virus (HIV). The term interim was used because the evidence was incomplete at that time. Since then, additional evidence has been generated from randomized controlled trials, observational studies, operational research and best practices from programmatic implementation of the collaborative TB/HIV activities recommended by the policy. Furthermore, a number of TB and HIV guidelines and policy recommendations have been developed by WHO's Stop TB and HIV/AIDS departments. Updated policy guidelines were therefore warranted to consolidate the latest available evidence and WHO recommendations on the management of HIV-related TB for national programme managers, implementers and other stakeholders.

The process of updating the policy was overseen by a WHO Steering Group and advised by a Policy Updating Group that followed WHO recommendations for developing guidelines. The Policy Updating Group comprised policy-makers, programme managers, experts in TB and HIV, donor agencies, civil society organizations including people living with HIV, and a grading of recommendations assessment, development and evaluation (GRADE) methodologist. The WHO Steering Group prepared the initial draft, which was circulated to the Policy Updating Group and discussed via e-mail and a conference call. The refined draft policy was reviewed again by the members of the Policy Updating Group and sent to a wide range of peer reviewers before finalization.

These policy guidelines on collaborative TB/HIV activities are a compilation of existing WHO recommendations on HIV-related TB. They follow the same framework as the 2004 interim policy document, structuring the activities under three distinct objectives: establishing and strengthening mechanisms for integrated delivery of TB and HIV services; reducing the burden of TB among people living with HIV and initiating early antiretroviral therapy; and reducing the burden of HIV among people with presumptive TB (that is, people with signs and symptoms of TB or with suspected TB) and diagnosed TB.

Unlike the 2004 document, the updated policy emphasizes the need to establish mechanisms for delivering integrated TB and HIV services, preferably at the same time and location. Those working to integrate the services should consider the epidemiology of HIV and TB, the health-system factors that are specific to individual countries, the management of HIV programmes and TB-control programmes and evidence-based models of service delivery. In addition, mechanisms for delivering the integrated services should be established as part of other health programmes such as maternal and child health, harm reduction services and prison health services. Monitoring and evaluation of collaborative TB/HIV activities should be done within one national system using standardized indicators and reporting and recording formats. TB prevalence surveys should include HIV testing, and HIV surveillance systems should incorporate TB screening as routine practice. The updated policy recommends setting national and local targets for collaborative TB/HIV activities through a participatory process (for example, through the national TB/HIV coordinating body and national consultations) to facilitate implementation and mobilize political commitment. Long-term and medium-term national strategic plans aligned with the health system of individual countries should be developed to scale up activities nationwide. National HIV programmes and TB-control programmes should establish linkage and partnerships with other line ministries

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28540](https://www.yunbaogao.cn/report/index/report?reportId=5_28540)

